Clinical efficacy of intravenous immunoglobulins for the treatment of dermatomyositis skin lesions without muscle disease

Bounfour, T.; Bouaziz, Jean‐David; Bézier, M.; Cordoliani, F.; Saussine, A.; Petit, Antoine; Juillard, C.; Bagot, M.; Rybojad, M.

doi:10.1111/jdv.12223

Cited by 33 publications

(20 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thirty‐one patients used IVIG, including two patients with acute ILD . In most cases 2 g kg −1 was given over two consecutive days and repeated at monthly intervals.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Treatment of clinically amyopathic dermatomyositis in adults: a systematic review

et al. 2016

View full text Add to dashboard Cite

Clinically amyopathic dermatomyositis (CADM) affects a subset of 5-20% of patients with dermatomyositis and is defined as the presence of cutaneous features of dermatomyositis without clinical muscle weakness for ≥ 6 months. There is no consensus on first-line treatment for CADM and whether treatment should differ from treatment of classic dermatomyositis with muscle weakness. We carried out a systematic review of published literature about treatment of adult patients with CADM, via the Embase, Medline, CINAHL and ClinicalTrials.gov databases on 17 February 2015. The aim was to establish which treatments have been used for adult-onset CADM and what evidence is available regarding the efficacy of these treatments including topical treatments, dapsone, antimalarials, intravenous immunoglobulin (IVIG), nonsteroidal oral immunosuppressants and biological therapies. Eighteen cases series and 42 case reports were found. These provided data on 153 adult patients who met the inclusion criteria. No randomized controlled trials or robust observational studies were found. The majority of patients (60%) had tried more than one treatment due to side-effects or lack of efficacy. Antimalarial agents were the most commonly used treatment type. In the majority of patients (55%), antimalarial treatments were discontinued due to lack of improvement or inability to wean concomitant steroids. IVIG was the treatment that led to improvement or remission in the greatest proportion of patients. Further robust, high-quality studies are needed to assess treatment efficacy in CADM without bias.

show abstract

“…Thirty‐one patients used IVIG, including two patients with acute ILD . In most cases 2 g kg −1 was given over two consecutive days and repeated at monthly intervals.…”

Section: Resultsmentioning

confidence: 99%

“…Side‐effects were headache (12 patients), nausea (five patients), fever (two patients) and hypertension (one patient). Two patients discontinued IVIG due to headaches on the first cycle …”

Section: Resultsmentioning

confidence: 99%

Treatment of clinically amyopathic dermatomyositis in adults: a systematic review

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Femia and colleagues retrospectively reviewed 13 patients with DM who showed clinical improvement with IVIG for refractory skin disease, and found that 8 of the patients achieved complete response . Similarly, Bounfour and colleagues retrospectively reviewed 27 patients with refractory cutaneous DM, finding that 23 patients showed skin improvement with IVIG treatment …”

Section: Discussionmentioning

confidence: 99%

“…7 Similarly, Bounfour and colleagues retrospectively reviewed 27 patients with refractory cutaneous DM, finding that 23 patients showed skin improvement with IVIG treatment. 8 In the current study, we assessed 42 patients with DM treated with IVIG for refractory DM skin disease with/ without refractory myositis and/or ILD, who had clinical data at time of DM diagnosis and IVIG initiation available for review. The majority (83%) showed cutaneous improvement with IVIG.…”

Section: Discussionmentioning

confidence: 99%

“…5 IVIG was also one of the few medications found to be efficacious for DM in a randomized trial, 6 but that trial and most other DM studies have focused on muscular rather than cutaneous outcomes, and the literature concerning treatment for refractory cutaneous DM is scarce. 7,8 We retrospectively reviewed patients with DM seen at a US tertiary care centre, who eventually received IVIG for refractory cutaneous DM. We report the clinical features of these patients and their skin response to IVIG.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Intravenous immunoglobulin is an effective treatment for refractory cutaneous dermatomyositis

Galimberti

Kooistra

et al. 2018

Clin Exp Dermatol

View full text Add to dashboard Cite

Use of IVIG resulted in improvement of refractory cutaneous DM in the vast majority of patients relatively soon after initiation and regardless of DM subtype or clinical manifestations. Additionally, IVIG allowed decrease or discontinuation of immunosuppressive medications in 80% of patients. These findings suggest that IVIG can be a clinically efficacious and cost-effective treatment for refractory cutaneous DM and warrants prospective study.

show abstract

Control of dermatomyositis skin disease activity lags behind control of muscles disease activity during the early treatment stages of classic dermatomyositis: A retrospective, single‐centre study

Bhatt,

Flatley,

Cooper

et al. 2024

Skin Health and Disease

View full text Add to dashboard Cite

show abstract

Clinical efficacy of intravenous immunoglobulins for the treatment of dermatomyositis skin lesions without muscle disease

Abstract: IVIg may be an effective and safe treatment for DM with isolated skin involvement. Relapse occurred frequently, but treatment with a new course of IVIg was successful. Controlled studies are required to confirm these results.

Cited by 33 publications

References 33 publications

Treatment of clinically amyopathic dermatomyositis in adults: a systematic review

Treatment of clinically amyopathic dermatomyositis in adults: a systematic review

Intravenous immunoglobulin is an effective treatment for refractory cutaneous dermatomyositis

Control of dermatomyositis skin disease activity lags behind control of muscles disease activity during the early treatment stages of classic dermatomyositis: A retrospective, single‐centre study

Contact Info

Product

Resources

About